These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012 [TBL] [Abstract][Full Text] [Related]
4. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659 [TBL] [Abstract][Full Text] [Related]
5. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. Reyes R; Wani NA; Ghoshal K; Jacob ST; Motiwala T Gene Expr; 2017 Feb; 17(2):129-140. PubMed ID: 27938509 [TBL] [Abstract][Full Text] [Related]
7. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. Lu M; Fei Z; Zhang G Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516 [TBL] [Abstract][Full Text] [Related]
8. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312 [TBL] [Abstract][Full Text] [Related]
9. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667 [TBL] [Abstract][Full Text] [Related]
10. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051 [TBL] [Abstract][Full Text] [Related]
11. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350 [TBL] [Abstract][Full Text] [Related]
12. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro. Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478 [TBL] [Abstract][Full Text] [Related]
13. Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition. Yang Y; Qin SK; Wu Q; Wang ZS; Zheng RS; Tong XH; Liu H; Tao L; He XD Oncol Rep; 2014 Feb; 31(2):540-50. PubMed ID: 24317203 [TBL] [Abstract][Full Text] [Related]
14. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777 [TBL] [Abstract][Full Text] [Related]
15. New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Brito AF; Ribeiro M; Abrantes AM; Mamede AC; Laranjo M; Casalta-Lopes JE; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF Nutr Cancer; 2016; 68(2):250-66. PubMed ID: 26943884 [TBL] [Abstract][Full Text] [Related]
16. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637 [TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. Cheng Y; Luo R; Zheng H; Wang B; Liu Y; Liu D; Chen J; Xu W; Li A; Zhu Y Oncotarget; 2017 Apr; 8(14):23265-23276. PubMed ID: 28423574 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439 [TBL] [Abstract][Full Text] [Related]
20. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]